Multiple myeloma (MM), a malignancy characterized by the proliferation of aberrant plasma cells closely interacting with the bone marrow milieu, has seen considerable advancements in overall survival (OS) over the last 15 years [1]. However, MM remains predominantly incurable, with most patients...
Chimeric antigen receptor T-cell (CAR-T) immunotherapy has been widely adopted as a promising strategy for the treatment of hematological malignancies (HMs), as well as other solid tumors and autoimmune diseases [1]. Notably, its efficacy in the treatment of HMs especially including B-cell lymphoma,...
T cell lineage acute lymphoblastic leukemia (ALL) is characterized by immunophenotypic and molecular high diversity. T-ALL represents 15% of pediatric and 25% of adult newly diagnosed ALL cases [1]. In frontline therapy, all patients with T-ALL are treated with similar multiagent chemotherapy regimens...
Acute myeloid leukemia (AML) is preceded by malignant clonal expansion of progenitor cells with impaired differentiation and is associated with the highest proportion of deaths among all types of leukemia [1, 2, 3–4]. In the United States, in 2024, there were 20,800 new cases of AML, accounting...
AML Classifications: WHO vs ICC 2022 Update The following is a summary of the article “Definitions of Acute Myeloid Leukaemia and their clinical significance according to the WHO 2022 and ICC classification” by Donata Backhaus et al (University of Leipzig Medical Center, Germany), which...